Starling Oncology (STLN) Financial statements
Starling Oncology reported revenue of $503M in fiscal 2025, up 21.8% a year over 5 years.
Key figures
Net income was -$61M and the operating margin -7.2%, against -4.4% in 2020. Free cash flow was -$28M. The diluted share count rose 56% over the period (dilution).
- Revenue, FY2025
- $503M+27.8% on 2024
- Net income
- -$61M-6.3% on 2024
- Operating margin
- -7.2%
- Free cash flow
- -$28M-8.4% on 2024
Revenue and free cash flow
Fiscal years, from Starling Oncology's 10-K filings.
Starling Oncology revenue and free cash flow
FY2020–FY2025Margins
How much of each dollar of revenue is left after the cost of sales, after operating costs, and at the bottom line.
Starling Oncology margins
FY2020–FY2025Financial statements
Fiscal 2020–2025.
Starling Oncology income statement, fiscal 2020–2025
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $188M | $203M | $252M | $324M | $393M | $503M |
| Selling, general and admin | $42M | $83M | $120M | $114M | $108M | $106M |
| Operating income | -$8M | -$46M | -$82M | -$77M | -$60M | -$36M |
| Interest expense | $347,000 | $320,000 | $4M | $7M | $7M | $11M |
| Pre-tax income | -$15M | -$12M | -$91,000 | -$83M | -$65M | -$61M |
| Income tax | -$493,000 | -$671,000 | -$243,000 | -$36,000 | $0 | -$131,000 |
| Net income | -$14M | -$11M | $152,000 | -$83M | -$65M | -$61M |
| EPS (diluted) | -$0.24 | -$0.16 | -$0.21 | -$0.92 | -$0.71 | -$0.54 |
| Diluted shares | 59M | 66M | 81M | 74M | 75M | 92M |
| Operating margin | -4.4% | -22.6% | -32.5% | -23.8% | -15.3% | -7.2% |
| Net margin | -7.6% | -5.4% | 0.1% | -25.6% | -16.4% | -12.1% |
Starling Oncology balance sheet, fiscal 2020–2025
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $916,987 | $115M | $74M | $83M | $50M | $34M |
| Receivables | $17M | $20M | $40M | $42M | $48M | $59M |
| Inventory | $4M | $6M | $9M | $14M | $10M | $17M |
| Total current assets | $30M | $154M | $130M | $143M | $112M | $113M |
| Property, plant and equipment | $2M | $4M | $9M | $11M | $12M | $11M |
| Goodwill | $14M | $27M | $21M | $7M | $7M | $7M |
| Total assets | $66M | $203M | $262M | $209M | $173M | $165M |
| Total current liabilities | $29M | $30M | $30M | $35M | $52M | $71M |
| Long-term debt | $7M | $0 | $81M | $87M | $93M | $77M |
| Total liabilities | $38M | $99M | $138M | $152M | $169M | $180M |
| Shareholders' equity | $28M | $104M | $123M | $57M | $4M | -$16M |
| Net debt | $11M | -$115M | $67M | $53M | $43M | $44M |
Starling Oncology cash flow, fiscal 2020–2025
| USD | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $508,000 | -$33M | -$62M | -$36M | -$27M | -$25M |
| Capital spending | $1M | $3M | $6M | $5M | $4M | $3M |
| Free cash flow | -$686,000 | -$36M | -$67M | -$41M | -$30M | -$28M |
| Stock-based compensation | $151,000 | $25M | $28M | $18M | $11M | $5M |
| Share buybacks (net) | — | $0 | -$9M | -$1M | $0 | — |
| Net borrowing | $12M | -$7M | $110M | $0 | $0 | -$20M |
| Free cash flow margin | -0.4% | -17.5% | -26.6% | -12.6% | -7.7% | -5.5% |
How Starling Oncology compares
Starling Oncology's operating margin is higher than 49% of Healthcare companies and 23% of the 2,818 companies with an operating margin figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| Operating margin | 49% | 23% |
| Net margin | 49% | 21% |
| Revenue growth | 77% | 86% |
Questions about Starling Oncology
What was Starling Oncology's revenue in 2025?
$503M in fiscal 2025, from its 10-K filing.
How much free cash flow does Starling Oncology generate?
-$28M in fiscal 2025 (operating cash flow minus capital spending).
From Starling Oncology's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.